Thomas Walley

3.8k total citations · 1 hit paper
26 papers, 2.6k citations indexed

About

Thomas Walley is a scholar working on Economics and Econometrics, General Health Professions and Surgery. According to data from OpenAlex, Thomas Walley has authored 26 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 6 papers in General Health Professions and 4 papers in Surgery. Recurrent topics in Thomas Walley's work include Health Systems, Economic Evaluations, Quality of Life (7 papers), Pharmaceutical Economics and Policy (5 papers) and Pharmacovigilance and Adverse Drug Reactions (4 papers). Thomas Walley is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (7 papers), Pharmaceutical Economics and Policy (5 papers) and Pharmacovigilance and Adverse Drug Reactions (4 papers). Thomas Walley collaborates with scholars based in United Kingdom, Netherlands and Italy. Thomas Walley's co-authors include Munir Pirmohamed, Alasdair Breckenridge, B Kevin Park, Andrew Scott, Keith Farrar, Chris Green, Alan Haycox, A Bagust, Stuart Barton and D. J. Webb and has published in prestigious journals such as The Lancet, Thorax and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Thomas Walley

24 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

2004 2.3k citations Munir Pirmohamed, Chris Green et al. BMJ profile →

Peers

Countries citing papers authored by Thomas Walley

Since Specialization

Citations

This map shows the geographic impact of Thomas Walley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Walley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Walley more than expected).

Fields of papers citing papers by Thomas Walley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Walley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Walley. The network helps show where Thomas Walley may publish in the future.

Co-authorship network of co-authors of Thomas Walley

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Walley. A scholar is included among the top collaborators of Thomas Walley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Walley. Thomas Walley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia 2018 ·Clinical Drug Investigation ·Alessandra Bettiol, Ettore Marconi, Niccolò Lombardi, Giada Crescioli, Filíppo Gherlinzoni, Thomas Walley, Alfredo Vannacci, Alessandro Chinellato, Pietro Giusti	8
2	Research to decrease areas of clinical uncertainty 2011 ·BMJ ·A J Farmer, Ruairidh Milne, Thomas Walley	2
3	Reconciling national treatment policies and drug regulation in Kenya 2007 ·Health Policy and Planning ·Abdinasir A Amin, Thomas Walley, Gilbert Kokwaro, PA Winstanley, Robert W. Snow	8
4	Considering the case for an antidepressant drug trial involving temporary deception: a qualitative enquiry of potential participants 2007 ·BMC Health Services Research ·Christopher Dowrick, John Hughes, Julia Hiscock, Mark Wigglesworth, Thomas Walley	8
5	Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients breakdown → 2004 ·BMJ ·Munir Pirmohamed, (unknown), (unknown), Chris Green, Andrew Scott, Thomas Walley, Keith Farrar, B Kevin Park, Alasdair Breckenridge	2286
6	Superiority and equivalence in thrombolytic drugs: an interpretation 2003 ·QJM ·Thomas Walley	6
7	Reporting of adverse drug reactions by nurses 2003 ·The Lancet ·(unknown), Thomas Walley, B Kevin Park, Alasdair Breckenridge, Munir Pirmohamed	76
8	Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: 2002 ·Controlled Clinical Trials ·Jerry Avorn, Josh Benner, Ian Ford, David A. Ganz, Allan Gaw, Robert J. Glynn, Jeanne Jackson, A. Margot Lagaay, Sebastian Schneeweiß, Thomas Walley, Philip S. Wang	5
9	Clinical guidelines---the hidden costs 1999 ·BMJ ·Alan Haycox, A Bagust, Thomas Walley	51
10	Review of therapeutically equivalent alternatives to short acting beta 2 adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers 1999 ·Thorax ·Dyfrig Hughes, Ashley Woodcock, Thomas Walley	13
11	Reporting of adverse drug reactions: practice in the UK. 1998 ·PubMed ·(unknown), Munir Pirmohamed, Thomas Walley	9
12	THE USE OF HEALTH ECONOMICS BY HOSPITAL PHARMACIST DECISION MAKERS : A SURVEY OF UK CHIEF PHARMACISTS 1997 ·Pharmaceutical journal/The pharmaceutical journal ·Jonathan Cooke, Thomas Walley, Michael Drummond	3
13	Core content of a course in Clinical Pharmacology 1997 ·British Journal of Clinical Pharmacology ·Thomas Walley, D. J. Webb	28
14	Pharmacoeconomics: evaluating the evaluators 1997 ·British Journal of Clinical Pharmacology ·Alan Haycox, Thomas Walley	14
15	Influences of practice characteristics on prescribing in fundholding and non-fundholding general practices: an observational study 1996 ·BMJ ·Robert Wilson, Juanita Hatcher, Stuart Barton, Thomas Walley	41
16	Cost Implications of Prehospital Emergency Drug Administration 1996 ·PharmacoEconomics ·Stuart Barton, Thomas Walley	2
17	Patient packs and the prescribing of antimicrobial agents 1996 ·Journal of Antimicrobial Chemotherapy ·H. Humphreys, Thomas Walley	1
18	Allergic Drug Reactions 1994 ·Clinical Immunotherapeutics ·Thomas Walley, John W. Coleman	3
19	Different Vasodilating Mechanisms—Different Peripheral Effects? 1992 ·Journal of Cardiovascular Pharmacology ·Alasdair Breckenridge, David H. Roberts, Thomas Walley	3
20	Cross-sectional echocardiography in the diagnosis of Libman-Sachs endocarditis 1988 ·International Journal of Cardiology ·Thomas Walley	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact